12.04.2012 - A £180m fund designed to bridge the ‘valley of death’ for medical breakthroughs in the UK will kick off at the end of April
London – A £180m government scheme designed to support collaboration between innovative SMEs and academics for developing solutions to healthcare challenges will open for applications at the end of April, according to announcements by the UK’s Technology Strategy Board The Biomedical Catalyst is a key element of the Strategy for Life Sciences launched by Prime Minister David Cameron in December 2011. It will see the Medical Research Council (MRC) and the Technology Strategy Board working together to take the best British medical breakthroughs through to commercial success. Announcing the opening of the fund at a life sciences roundtable event in Japan, Minister for Universities and Science David Willetts said, “The Government is absolutely committed to ensuring the future success of the UK’s life sciences industry and one of the key challenges is tackling the so-called ‘valley of death’. This exists between the moment that a bright new idea is developed in the laboratory and the point when a new drug or technology can be invested in by the market. The £180 million Biomedical Catalyst program will bridge this funding gap.”Under the Biomedical Catalyst scheme, three categories of grant awards will be available – feasibility, early stage and late stage clinical research. Individual grants to businesses will range from a maximum of £150,000 for feasibility awards to £3 million for early and late stage awards. Projects could focus on stratified therapy development, regenerative medicine, diagnostics, eHealth and mHealth solutions, enabling medical technologies and devices. The announcement complements a £200m VC funding initiative termed Project Sigma launched in March by the British Wellcome Trust .
26.08.2016 Adocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products.
24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.
23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.
19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.
17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).
15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).
09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.
08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.
FILTRODISC™ BIO SD is a filtration system which removes particles (e.g. cells, bacteria, yeast), impurities (e.g. HCP, DNA) and other turbid matter from process liquids (e.g. fermentation broths). more